WHODrug: A Global, Validated and Updated Dictionary for Medicinal Information
Tóm tắt
The WHODrug medicinal information dictionary is a worldwide source of global medicinal information with the aim to facilitate the coding of medications in clinical trials as well as identification of medication-related problems when monitoring patient safety, thereby supporting the development and usage of effective and safe medications. WHODrug contains individual trade names, active ingredients and additional information such as marketing authorisation holder, country of sale, pharmaceutical form and strength. All related medications are linked using a structured WHODrug alphanumeric code, connecting trade names and variation of the ingredient with the active moiety of the ingredient. Medications in WHODrug are classified using the ATC system and clustered into Standardised Drug Groupings, to allow for grouping of medications with one or more properties in common. The built-in data structure and the classification of medications in WHODrug facilitate various ways of aggregating medications for identification and analysis of possible adverse drug reactions. The different information levels in WHODrug are used to explore the relationship between a medication or a class of medications and an adverse event. By using WHODrug in clinical trials and post-marketing safety, accurate and standardised medication information can be achieved globally and allow easy information exchange. To meet the demands of WHODrug users from the pharmaceutical industry, academia and regulatory authorities, it is relevant to keep the dictionary comprehensive, validated and constantly updated on a global scale.
Từ khóa
Tài liệu tham khảo
Lu Z. Technical challenges in designing post-marketing eCRFs to address clinical safety and pharmacovigilance needs. Contemp Clin Trials. 2010;31(1):108–18.
Nair GJ. Ensuring quality in the coding process: a key differentiator for the accurate interpretation of safety data. Perspect Clin Res. 2013;4(3):181–5.
FDA. FDA Data Standards Catalog v5.2 (12-20-2018). In. https://www.fda.gov/industry/fda-resources-data-standards/study-data-standards-resources: FDA.
PMDA. Notification on Practical Operations of Electronic Study Data Submissions In: Bureau PaFS, ed. https://www.pmda.go.jp/english/review-services/reviews/0002.html: PMDA; 2019.
Bejan-Angoulvant T, Genet T, Vrignaud L, Angoulvant D, Fauchier L. Three case reports of involuntary muscular movements as adverse reactions to sacubitril/valsartan. Br J Clin Pharmacol. 2018;84(5):1072–4.
Juhlin K, Karimi G, Andér M, et al. Using VigiBase to identify substandard medicines: detection capacity and key prerequisites. Drug Saf. 2015;38(4):373–82.
van Stekelenborg J, Ellenius J, Maskell S, et al. Recommendations for the use of social media in pharmacovigilance: lessons from IMI WEB-RADR. Drug Saf. 2019;42(12):1393–407.
Ellenius JBT, Dasgupta N, Hedfors S, Pierce C, Norén GN. Medication name entity recognition in tweets using global dictionary lookup and word sense disambiguation. Pharmacoepidemiol Drug Saf. 2016;25(S3):414–5.
Star K, Sandberg L, Bergvall T, Choonara I, Caduff-Janosa P, Edwards IR. Paediatric safety signals identified in VigiBase: methods and results from Uppsala Monitoring Centre. Pharmacoepidemiol Drug Saf. 2019;28(5):680–9.
Wakao R, Taavola H, Sandberg L, et al. Data-driven identification of adverse event reporting patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports. Drug Saf. 2019;42(12):1487–98.
Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res Part C. 2015;105(2):140–56.
The WHO Programme for International Drug Monitoring. 2019; https://www.who.int/medicines/areas/quality_safety/safety_efficacy/National_PV_Centres_Map/en/.
Lindquist M. VigiBase, the WHO Global ICSR Database System: basic Facts. Drug Inf J. 2008;42(5):409–19.
Helling M, Venulet J. Drug recording and classification by the WHO research centre for international monitoring of adverse reactions to drugs. Methods Inf Med. 1974;13(3):169–78.
Venulet J, Borda MH. WHO’s international drug monitoring—the formative years, 1968–1975. Drug Saf. 2010;33(7):e1–23.
FDA US. 21 e-C.F.R. §314:3, 19 December. In: 2019.
WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment, 2019. Oslo, 2018. In:2019.
Watson S, Härmark L. Desogestrel and panic attacks—a new suspected adverse drug reaction reported by patients and health care professionals on spontaneous reports. Br J Clin Pharmacol. 2018;84(8):1858–9.
Heiko Baermann; Matthias Frischmann. Drug Groupings and workflow options for the processing and review of concomitant medication data. PhUSE Annual Conference—Brussels 14th October. 2013.
Rebecca E, Chandler OL. The utilisation of a new tool in signal management—WHODrug Standardised Drug Groupings. ICPE; 2019; Philadelphia.
PMDA. Notification on Practical Operations of Electronic Study Data Submissions In: Bureau PaFS, ed. https://www.pmda.go.jp/english/review-services/reviews/advanced-efforts/0002.html: PMDA; 2015.